Extracorporeal removal of lipids by dextran sulfate cellulose adsorption.
Extracorporeal removal of low-density lipoprotein (LDL) cholesterol by dextran sulfate adsorption is indicated in patients with diet and drug resistant hyper-cholesterolemia to prevent or to regress coronary heart disease. Plasma separation is the first step in the process, followed by adsorption of LDL cholesterol and lipoprotein (a) (Lp[a]) to negatively charged dextran sulfate covalently bound to cellulose beads. The reduction per treatment in LDL cholesterol is 65-75% and in Lp(a) 40-60%. In most patients one treatment per week is sufficient to reduce mean LDL to 100-150 mg/dl. Minor side effects occur in 2-6% of treatments. Major side effects are rare. In uncontrolled studies long-term treatment was associated with inhibition of progression and induction of regression of coronary artery disease. LDL apheresis by dextran sulfate may increase blood perfusion of some tissues, and preliminary results indicate a beneficial effect on therapy resistant nephrotic syndrome with hypercholesterolemia.
Olbricht
C J
CJ
Department of Nephrology, Medical School Hannover, Germany.
D000327:Adsorption; D001798:Blood Proteins / Q000302:isolation & purification / Q000378:metabolism; D002482:Cellulose / Q000737:chemistry / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood / Q000302:isolation & purification*; D015243:Cholesterol, VLDL / Q000097:blood / Q000302:isolation & purification; D016264:Dextran Sulfate / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy*; D010956:Plasmapheresis; D014280:Triglycerides / Q000097:blood / Q000302:isolation & purification
D001798:Blood Proteins; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D014280:Triglycerides; D002482:Cellulose; D016264:Dextran Sulfate